Details of the Drug Combination

General Information of Drug Combination (ID: DCGLC84)

Drug Combination Name

Trimethobenzamide PFK-158

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

Trimethobenzamide DMPP4DT

PFK-158 DMIR21F

Small molecular drug

N.A.

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 10.93

Bliss Independence Score: 10.93

Loewe Additivity Score: 16.79

LHighest Single Agent (HSA) Score: 16.81

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Trimethobenzamide

Disease Entry	ICD 11	Status	REF
Nausea	MD90	Approved	[2]
Nausea and vomiting	MD90	Approved	[3]
Vomiting	MD90	Approved	[2]

Indication(s) of PFK-158

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

PFK-158 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Renal carcinoma antigen NY-REN-56 (PFKFB3)	TTTHMQJ	F263_HUMAN	Inhibitor	[5]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Trimethobenzamide FDA Label
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	ClinicalTrials.gov (NCT02044861) Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies. U.S. National Institutes of Health.
5	Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab. 2014; 2(Suppl 1): P14.